Q1 FY2026 · ended Mar 31, 2026 · Revenue $1.25M, -69.8% YoY · Filed Aug 10, 2026
Metagenomi Therapeutics, Inc. (MGX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$19.6 million. As of Jun 30, 2026 it held $122.8 million in cash and investments and $37.7 million in total debt.
Revenue
$1.25M
-69.8% vs year-ago quarter
Net income
$-27.48M
-38.0% vs year-ago quarter
Operating cash flow
$-19.51M
+8.2% vs year-ago quarter
Free cash flow
$-19.64M
+8.1% vs year-ago quarter
EPS
$-0.73
-35.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
37.78M
+0.7% vs year-ago quarter
Net cash
$85.10M
Q2 FY2026
Operating margin
-415.5%
TTM
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MGX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1785279
- Former names
- Metagenomi, Inc. (until Jan 12, 2026); Metagenomi Technologies, LLC (until Jan 18, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | $1.2M | $3.9M | $8.7M | $8.5M |
| Operating income | -$28.8M | -$24.6M | -$24.4M | -$22.8M | -$21.0M |
| Net income | -$27.5M | -$23.1M | -$22.5M | -$20.4M | -$19.9M |
| Diluted EPS | -$0.73 | -$0.61 | -$0.60 | -$0.55 | -$0.54 |
| Operating cash flow | -$19.5M | -$21.2M | -$23.5M | -$21.3M | -$21.3M |
| Free cash flow | -$19.6M | -$21.2M | -$23.6M | -$21.3M | -$21.4M |
| Total assets | $173.7M | $197.0M | $221.1M | $247.9M | $272.3M |
| Total liabilities | $61.1M | $59.2M | $62.5M | $69.5M | $76.5M |
| Stockholders' equity | $112.6M | $137.8M | $158.6M | $178.4M | $195.8M |
| Cash and investments | $122.8M | $142.3M | $163.0M | $186.3M | $207.1M |
| Total debt | $37.7M | $39.2M | $40.7M | $41.7M | $43.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 22, 2026 | Sep 21, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 11, 2026 | May 11, 2026 |
All 154 Metagenomi Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.